Rong Wang1, Qing Lv1, Wentong Meng1, Qiuwen Tan1, Shu Zhang1, Xianming Mo1, Xiaoqin Yang1. 1. 1 Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, China ; 2 Department of Breast Surgery, the Affiliated Hospital of Guiyang Medical College, Guiyang 550000, China ; 3 Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Abstract
BACKGROUND: Breast cancer stem cells (BCSCs) can be enriched by culturing of cells in non-adherent non-differentiating conditions. However, culturing mammospheres from primary breast tumors are costly and difficult to control. In order to overcome problems associated with using primary human tissues, continuous breast cancer cell lines have been developed from various sources. METHODS: In this study, a luminal subtype breast cancer cell line MCF-7 and a basal subtype cell line MDA-MB-231 were chosen. We explored the optimal culturing system for BCSCs from the two cell lines and primary breast tumors. Then, mammosphere formation efficiency (MFE), CD44(+)/CD24(-/low)ESA(+)Lin(-) cell proportion in mammospheres, and tumorigenecity of mammospheres generated from the two breast cancer cell lines and primary breast tumors were compared. RESULTS: Enzymatic digestion of 60 mins and the addition of B27 to the culture medium were optimal for mammosphere culturing. Mammospheres could be formed in all the three cells, in which MCF-7 had the highest MFE. After 3 weeks culture, CD44(+)/CD24(-/low)ESA(+)Lin(-) cell proportion in mammospheres from MCF-7, MDA-MB-231 cells and primary breast tumors was 95.0%±2.5%, 82%±22% and 21.5%±1.0%, respectively. A total of 1,000 cells from MCF-7, MDA-MB-231 mammospheres but not primary mammospheres were tumorigenic. CONCLUSIONS: This study validates the use of breast cancer cell lines as models to elucidate the nature of BCSCs.
BACKGROUND:Breast cancer stem cells (BCSCs) can be enriched by culturing of cells in non-adherent non-differentiating conditions. However, culturing mammospheres from primary breast tumors are costly and difficult to control. In order to overcome problems associated with using primary human tissues, continuous breast cancer cell lines have been developed from various sources. METHODS: In this study, a luminal subtype breast cancer cell line MCF-7 and a basal subtype cell line MDA-MB-231 were chosen. We explored the optimal culturing system for BCSCs from the two cell lines and primary breast tumors. Then, mammosphere formation efficiency (MFE), CD44(+)/CD24(-/low)ESA(+)Lin(-) cell proportion in mammospheres, and tumorigenecity of mammospheres generated from the two breast cancer cell lines and primary breast tumors were compared. RESULTS: Enzymatic digestion of 60 mins and the addition of B27 to the culture medium were optimal for mammosphere culturing. Mammospheres could be formed in all the three cells, in which MCF-7 had the highest MFE. After 3 weeks culture, CD44(+)/CD24(-/low)ESA(+)Lin(-) cell proportion in mammospheres from MCF-7, MDA-MB-231 cells and primary breast tumors was 95.0%±2.5%, 82%±22% and 21.5%±1.0%, respectively. A total of 1,000 cells from MCF-7, MDA-MB-231 mammospheres but not primary mammospheres were tumorigenic. CONCLUSIONS: This study validates the use of breast cancer cell lines as models to elucidate the nature of BCSCs.
Entities:
Keywords:
Breast cancer stem cells (BCSCs); MCF-7; MDA-MB-231; flow cytometry; mammosphere; primary breast tumor; tumorigenicity
Authors: Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl Journal: Cancer Res Date: 2006-09-21 Impact factor: 12.701
Authors: Axel Schulenburg; Herbert Ulrich-Pur; Dietmar Thurnher; Boban Erovic; Stefan Florian; Wolfgang R Sperr; Peter Kalhs; Brigitte Marian; Friedrich Wrba; Christoph C Zielinski; Peter Valent Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: Lubna Patrawala; Tammy Calhoun; Robin Schneider-Broussard; Jianjun Zhou; Kent Claypool; Dean G Tang Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: Muhammad Al-Hajj; Michael W Becker; Max Wicha; Irving Weissman; Michael F Clarke Journal: Curr Opin Genet Dev Date: 2004-02 Impact factor: 5.578
Authors: Carol Sheridan; Hiromitsu Kishimoto; Robyn K Fuchs; Sanjana Mehrotra; Poornima Bhat-Nakshatri; Charles H Turner; Robert Goulet; Sunil Badve; Harikrishna Nakshatri Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Megan C Madonna; Douglas B Fox; Brian T Crouch; Jihong Lee; Caigang Zhu; Amy F Martinez; James V Alvarez; Nirmala Ramanujam Journal: Mol Cancer Res Date: 2019-03-22 Impact factor: 5.852
Authors: Benjamin Newcomb; Cosima Rhein; Izolda Mileva; Rasheed Ahmad; Christopher J Clarke; Justin Snider; Lina M Obeid; Yusuf A Hannun Journal: J Lipid Res Date: 2018-05-03 Impact factor: 5.922